Avid Bioservices Inc (CDMO)

[jazzbeerman]

Duke/bavi PPHM CEO quotes -

Please note,as mentioned below, Duke is working with more of Peregrine's stuff than just Bavituximab. Personally, I would expect them to be looking into EVERYHING Peregrine's got, which includes, off the top of my head:

Bavi
humanized Bavi
other earlier anti-PS as mentioned in Thorpe patents, (9D2, etc.)
3G4
2aG4
the Betabodies
Chen's mabs, (IS1, etc.)
anti-PS conjugated to IFN
anti-PS conjugated to IL-2
mabs created through their collaboration with Affitech
mabs and conjugates created through their collaboration with Biotecnol
PS-binding peptides
PE-binding peptides
PE-targeting mabs
PE-binding peptide conjugates (DLB etc...)
likely several others I've forgotten...

j

9-11-06 QTLY. CONF. CALL (KING/LYTLE): http://tinyurl.com/k7uo6

SK: “BAVI HIV INITIATIVE: HIV is currently our primary area of interest for potential new AV indications... We have already generated positive data supporting the fact that Bavi recognizes both HIV virus and HIV infected cells. In order to fully evaluate the potential of Bavi in HIV therapy, we have expanded our collaborations in the HIV area. Our curr. collaborators include investigators at Tulane National Primate Research Center, Duke Univ., as well as contract research labs.




10-24-06 ANNUAL SHM, incl. Thorpe presentation on Bavi AC/AV http://tinyurl.com/vmasl

SK: “On the pre-clinical front, we are continuing our collab’s for AV applications, with the primary focus on HIV. Those studies are ongoing at Tulane & Duke, as well as at contract labs.”



3-12-07 QTLY. CONF. CALL (KING/LYTLE): http://tinyurl.com/2dtmca

SK: “Expanding the patient population we are treating to potentially include HCV/HIV co-infected individuals is a 3rd focus area… Our interest in this patient population has been further stimulated by solid evidence, thru our collab’s at Duke, that Bavi binds to HIV virus, binds to HIV-infected cells, and may have potent neutralizing effects on the virus.




3-12-07 QTLY. CONF. CALL (KING/LYTLE): http://tinyurl.com/2dtmca

SK: “ the funding that's coming out of there [Duke] is actually funding a lot of studies that are being done with bavituximab as a model..."

"The collaboration is going extremely well, the data we're generating is really helping us in the way we think about our development of bavituximab for HCV & HIV,"




7-11-07 QTLY. CONF. CALL (KING/LYTLE): http://tinyurl.com/2c9kwr

SK: “We have also been collaborating with researchers at Duke and other institutions to better understand the potential of Bavituximab in an HIV setting. Significant findings of these studies include data supporting Bavituximab binding to mult. strains of HIV and binding to HIV-infected cells



9-10-07 QTLY. CONF. CALL (KING/LYTLE): http://tinyurl.com/38lky9

SK: “Our collab. with HIV researchers at Duke remains strong and is making good progress. The collab. is providing exciting, new insights into the potential of Bavituximab.."

"we are happy with the collaboration and are getting a lot of data from the studies they are doing,"

"Our role in the studies is primarily to provide materials that are then being tested"..

"We are working with a group at Duke. In particular, we participated in a pgm that has been funded through the Gates Foundation [CAVD]. The CHAVI pgm is actually a separate pgm. They are both studying phospholipids as potential targets for the dev. of vaccines. So, in order to pursue that, they’ve been testing Bavituximab.."


There are add’l studies being planned. It’s a very large pgm that’s being run, again, simultaneously through these 2 different pgms – the CHAVI and then the Gates pgm [CAVD]. We are as anxious as anyone else to be able to get some of this info. out there. I know the guys at Duke will want to get it out there at the appropriate time. We are getting a lot of insight into, not just Bavituximab, but other antibodies that we have generated through our various collaborations. Over the long run, that’s going to be some extremely valuable info. that is only going to strengthen our overall antiviral pgm.”



2-10-07 QTLY. CONF. CALL (KING/LYTLE): http://tinyurl.com/393mau

SK: DUKE – “In addition to the clinical study, we are continuing a significant amount of preclinical work in the antiviral area. Our leading collaboration is with researchers at Duke University and a number of other institutions, including Harvard. This collaboration is progressing very nicely and we are highly encouraged by the results we have seen. As a reminder, we are exploring the potential of Bavituximab and several other anti-PS antibodies for their potential in the treatment and prevention of HIV infections. This collaboration is particularly important because without the collaboration we would not be able to conduct this informative research into the potential of our anti-PS platform for the treatment of HIV. Both we and our collaborators believe we are getting close to being able to share results of these studies either through publications or presentations in the upcoming months.”




the first and last slides of Rolf Brekken's Bavi preclinical studies ppt presentation -








BTW- Please review Brekken's eye-opening Bavituximab presentation in it's entirety -
http://presentations.cancerconferences.com/7th_monoclonal/files/2007_0817/ws02_brekken.pdf



-------


j